Renal pathology

Author(s):  
James Carton

Chronic kidney disease 142Acute renal failure 144Hypertensive nephropathy 145Diabetic nephropathy 146Minimal change disease 147Focal segmental glomerulosclerosis 148Membranous nephropathy 149IgA nephropathy 150Acute tubular injury 151Acute drug-induced interstitial nephritis 152Anti-glomerular basement membrane disease 153Reflux nephropathy 154...

Hypertension ◽  
2020 ◽  
Vol 76 (6) ◽  
pp. 1906-1914
Author(s):  
Yoshiki Aibara ◽  
Ayumu Nakashima ◽  
Ki-ichiro Kawano ◽  
Farina Mohamad Yusoff ◽  
Fumitaka Mizuki ◽  
...  

The estimated morbidity rate of chronic kidney disease is 8% to 16% worldwide, and many patients with chronic kidney disease eventually develop renal failure. Thus, the development of new therapeutic strategies for preventing renal failure is crucial. In this study, we assessed the effects of daily low-intensity pulsed ultrasound (LIPUS) therapy on experimental hypertensive nephropathy and diabetic nephropathy. Unilateral nephrectomy and subcutaneous infusion of angiotensin II via osmotic mini-pumps were used to induce hypertensive nephropathy in mice. Immunohistochemistry revealed that daily LIPUS treatment ameliorated renal fibrosis and infiltration of inflammatory cells induced by angiotensin II. A similar therapeutic effect was also observed in mice with angiotensin II-induced hypertensive nephropathy in which splenectomy was performed. In addition, LIPUS treatment significantly decreased systolic blood pressure after 21 days. Subsequently, db/db mice with unilateral nephrectomy developed proteinuria; daily LIPUS treatment significantly reduced proteinuria after 42 days. In addition, immunohistochemistry revealed that renal fibrosis was significantly ameliorated by LIPUS treatment. Finally, LIPUS stimulation suppressed TGF-β1 (transforming growth factor-β1)-induced phosphorylation of Smad2 and Smad3 in HK-2 (human proximal tubular cell line) cells. LIPUS treatment may be a useful therapy for preventing the progression of renal fibrosis in patients with chronic kidney disease.


2004 ◽  
Vol 19 (10) ◽  
pp. 2642-2646 ◽  
Author(s):  
M. A. Cameron ◽  
U. Peri ◽  
T. E. Rogers ◽  
O. W. Moe

Renal Failure ◽  
2010 ◽  
Vol 32 (8) ◽  
pp. 1012-1015 ◽  
Author(s):  
Jordan Y.Z. Li ◽  
Tuck Y. Yong ◽  
Bryone J. Kuss ◽  
Sonja Klebe ◽  
Dusan Kotasek ◽  
...  

2015 ◽  
Vol 5 (6) ◽  
pp. 836-841
Author(s):  
Eleni Chelioti ◽  
Alexia Papalexandrou ◽  
Evdokia Efthymiou ◽  
Maria Tsilivigkou

1989 ◽  
Vol 61 (03) ◽  
pp. 522-525 ◽  
Author(s):  
M P Gordge ◽  
R W Faint ◽  
P B Rylance ◽  
H Ireland ◽  
D A Lane ◽  
...  

SummaryD dimer and other large fragments produced during the breakdown of crosslinked fibrin may be measured by enzyme immunoassay using monoclonal antibodies. In 91 patients with renal disease and varying degrees of renal dysfunction, plasma D dimer showed no correlation with renal function, whereas FgE antigen, a fibrinogen derivative which is known to be cleared in part by the kidney, showed a significant negative correlation with creatinine clearance. Plasma concentrations of D dimer were, however, increased in patients with chronic renal failure (244 ± 3l ng/ml) (mean ± SEM) and diabetic nephropathy (308 ± 74 ng/ml), when compared with healthy controls (96 ± 13 ng/ml), and grossly elevated in patients with acute renal failure (2,451 ± 1,007 ng/ml). The results indicate an increase in fibrin formation and lysis, and not simply reduced elimination of D dimer by the kidneys, and are further evidence of activated coagulation in renal disease. D dimer appears to be a useful marker of fibrin breakdown in renal failure.


1989 ◽  
Vol 23 (4) ◽  
pp. 315-317 ◽  
Author(s):  
Barbro Spångberg-Viklund ◽  
Tomas Nikonoff ◽  
Marc Lundberg ◽  
Rutger Larsson ◽  
Tommy Skau ◽  
...  

Sexual Health ◽  
2011 ◽  
Vol 8 (4) ◽  
pp. 485 ◽  
Author(s):  
Claire Naftalin ◽  
Bavithra Nathan ◽  
Lisa Hamzah ◽  
Frank A. Post

Acute renal failure and chronic kidney disease are more common in HIV-infected patients compared with the general population. Several studies have shown age to be a risk factor for HIV-associated kidney disease. The improved life expectancy of HIV-infected patients as a result of widespread use of antiretroviral therapy has resulted in progressive aging of HIV cohorts in the developed world, and an increased burden of cardiovascular and kidney disease. Consequently, HIV care increasingly needs to incorporate strategies to detect and manage these non-infectious co-morbidities.


Sign in / Sign up

Export Citation Format

Share Document